Sonia Robinson
Family · Raleigh, NCNPI 1538899810
Payments from drug & device makers
Across 222 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$772
- AbbVie$648
- Vanda Pharmaceuticals Inc.$630
- Johnson & Johnson$603
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$536
- Alkermes, Inc.$401
- plus $1K from 18 others
What the payments were for
- Food & beverage$4,726100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 37 | $772 |
| AbbVie | 51 | $648 |
| Vanda Pharmaceuticals Inc. | 29 | $630 |
| Johnson & Johnson | 13 | $603 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $536 |
| Alkermes, Inc. | 15 | $401 |
| Neurocrine Biosciences, Inc. | 9 | $344 |
| Medtronic | 1 | $130 |
| Lundbeck LLC | 6 | $122 |
| Indivior Inc. | 5 | $104 |
| E.r. Squibb & Sons, L.L.C. | 4 | $91 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Noven Therapeutics, LLC | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Almatica Pharma LLC | 2 | $29 |
| Orexo US, Inc. | 2 | $28 |
| Corium, LLC | 1 | $23 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $15 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$435
- INVEGA SUSTENNA$253
- INTELLIS ADAPTIVESTIM$130
- CAPLYTA$128
- INGREZZA$121
- Fanapt$120
- ARISTADA INITIO$109
- VRAYLAR$105
How this compares
$4,738 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 75 | $107,655 |
| IngrezzaValbenazine Tosylate | 12 | $100,445 |
| RexultiBrexpiprazole | 31 | $50,860 |
| Invega SustennaPaliperidone Palmitate | 17 | $45,222 |
| CaplytaLumateperone Tosylate | 12 | $20,643 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 109 | $10,575 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 15 | $7,020 |
| Loreev XrLorazepam | 12 | $5,267 |
| Paliperidone ErPaliperidone | 44 | $5,013 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,766 |
| VascepaIcosapent Ethyl | 11 | $3,773 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $3,667 |
| ViibrydVilazodone Hcl | 11 | $3,589 |
| Clozapine | 43 | $3,096 |
| Quetiapine Fumarate | 177 | $2,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Viibryd | $648 | $111,24486 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $344 | $100,44512 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $772 | $50,86031 claims |
| Johnson & JohnsonInvega Sustenna | $603 | $45,22217 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $536 | $20,64312 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $29 | $7,321144 claims |
| Orexo US, Inc.Zubsolv | $28 | $7,02015 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $17 | $4,76613 claims |
| Indivior Inc.Suboxone | $104 | $3,66711 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $55 | $2,29214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in Raleigh
- Michele CerraRaleigh$332K
- Carrie PettitRaleigh$298K
- Jennifer GibbsRaleigh$216K
- Holly StarnesRaleigh$69K
- Harry LayRaleigh$63K
- Lauren HendricksRaleigh$17K
- Margaretann HouseRaleigh$16K
- Gretchen ReichmannRaleigh$13K
- Leslie ByrneFayetteville$482K
- Anne LakeArchdale$306K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.